Novo Nordisk A/S, often referred to as NVO, is a leading global healthcare company founded in 1923. The company is headquartered in Denmark and operates in more than 170 countries worldwide. NVO is a global leader in diabetes care and has expertise in haemophilia care, growth hormone therapy, and hormone replacement therapy. Furthermore, they are also committed to developing new innovative biological therapies.
The company has a rich history underscored by a commitment to develop and deliver innovative medications to patients with serious chronic conditions. At the heart of Novo Nordisk’s operations is a focus on transforming the lives of millions of people, the majority of these suffering from chronic diseases. Their passion for helping people, their commitment to long-term management of chronic diseases and their unique culture are what continues to set them apart.
Novo Nordisk A/S has spent decades focusing on research and development within chronic disease management. NVO boasts a strong portfolio of products and projects, most of them designed for people with diabetes, obesity, rare bleeding disorders, growth-related conditions. The drugs made by the company are known globally and hold significant market share in their respective categories.
In addition to its core products, the company is actively pursuing significant research and development programs. These initiatives are not only broadening the scope of its business but also helping to solidify its position as a leading innovator in healthcare. The company’s R&D strategy focuses on a patient-centered approach and aims to modify or halt disease progression and improve the quality of life of people living with these diseases.
NVO devotes considerable resources to help ensure that the benefits of their life-changing medications reach those who need them. They are renowned for their contribution to global health, highlighting their commitment to corporate social responsibility. Novo Nordisk A/S works closely with non-profit organizations, charities, and health organizations worldwide to help manage chronic disease and enhance access to medication and treatment.
The company's vision is to defeat diabetes and other serious chronic diseases. It is driven by the conviction that these are not simply about treatment, but also about prevention and early intervention. Today, Novo Nordisk A/S is one of the world’s most sustainable companies and is widely recognized for its significant contributions to global health.
In conclusion, Novo Nordisk A/S is a pioneering, patient-focused global healthcare company. With a legacy of more than 90 years, it stands at the forefront of changing the future of diabetes care and other serious chronic diseases, while being ambitiously committed to creating a positive impact on society and the environment.